Systematic screening for polymorphisms in the CYP3A4 gene in the Chinese population

Pharmacogenomics

Volumn 7, Issue 6, 2006, Pages 831-841

  Du, Jing ^a,b   Xing, Qinghe ^a,b   Xu, Lingyun ^c   Xu, Mingsheng ^d   Shu, Anli ^e   Shi, Yongyong ^a,b   Yu, Lan ^a,b   Zhang, Aiping ^a,b   Wang, Lei ^a,b   Wang, Hongsheng ^a,b   Li, Xingwang ^a,b   Feng, Guoyin ^f   He, Lin ^a,b  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b INSTITUTE OF GEOLOGY AND GEOPHYSICS   (China)

^c WANNAN MEDICAL COLLEGE   (China)

^d Anhui Institute of Parasitic Diseases   (China)

^e HUAIHUA MEDICAL COLLEGE   (China)

^f SHANGHAI MENTAL HEALTH CENTER   (China)

Author keywords

Chinese; CYP3A4; Cytochrome P450 3A; Single nucleotide polymorphism

Indexed keywords

ADENINE; CYTOCHROME P450 3A4; CYTOSINE; DNA; DRUG; GUANINE; TYROSINE;

3' UNTRANSLATED REGION; 5' UNTRANSLATED REGION; ADULT; AMINO ACID SUBSTITUTION; ARTICLE; CHINESE; CONTROLLED STUDY; DNA SEQUENCE; DRUG METABOLISM; FEMALE; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENETIC ANALYSIS; GENETIC POLYMORPHISM; GENETIC SCREENING; GENETIC VARIABILITY; GENOTYPE PHENOTYPE CORRELATION; HAPLOTYPE; HUMAN; HUMAN CELL; INTRON; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; POPULATION GENETICS; SEQUENCE ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; VOLUNTEER;

ADULT; AGED; ALLELES; ASIAN CONTINENTAL ANCESTRY GROUP; BASE SEQUENCE; CHINA; CYTOCHROME P-450 ENZYME SYSTEM; DNA PRIMERS; FEMALE; GENE FREQUENCY; GENETIC SCREENING; HAPLOTYPES; HUMANS; LINKAGE DISEQUILIBRIUM; MALE; MIDDLE AGED; PHARMACOGENETICS; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 33749034993     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/14622416.7.6.831     Document Type: Article

References (40)

1. Nelson DR, Koymans L, Kamataki T et al.: P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics 6, 1-42 (1996).
2. Finta C, Zaphiropoulos PG: The human cytochrome P450 3A locus. Gene evolution by capture of downstream exons. Gene 260, 13-23 (2000).
3. Gellner K, Eiselt R, Hustert E et al.: Genomic organization of the human CYP3A locus: identification of a new, inducible CYP3A gene. Pharmacogenetics 11, 111-121 (2001).
4. Thummel KE, Wilkinson GR: In vitro and in vivo drug interactions involving human CYP3A. Annu. Rev. Pharmacol. Toxicol. 38, 389-430 (1998).
5. Shimada T, Gillam EM, Sandhu P, Guo Z, Tukey RH, Guengerich FP: Activation of procarcinogens by human cytochrome P450 enzymes expressed in Escherichia coli. Simplified bacterial systems for genotoxicity assays. Carcinogenesis 15, 2523-2529 (1994).
6. Oesterheld JR: A review of developmental aspects of cytochrome P450. J. Child Adolesc. Psychopharmacol. 8, 161-174 (1998).
7. Westlind A, Lofberg L, Tindberg N, Andersson TB, Ingelman-Sundberg M: Interindividual differences in hepatic expression of CYP3A4: relationship to genetic polymorphism in the 5′-upstream regulatory region. Biochem. Biophys. Res. Commun. 259, 201-205 (1999).
8. Zhu B, Liu ZQ, Chen GL et al.: The distribution and gender difference of CYP3A activity in Chinese subjects. Br. J. Clin. Pharmacol. 55, 264-269 (2003).
9. Guengerich FP: Cytochrome P450 3A4: regulation and role in drug metabolism. Annu. Rev. Pharmacol. Toxicol. 39, 1-17 (1999).
10. Wrighton SA, Molowa DT, Guzelian PS: Identification of a cytochrome P450 in human fetal liver related to glucocorticoid-inducible cytochrome P450HLp in the adult. Biochem. Pharmacol. 37, 3053-3055 (1988).
11. Westlind A, Malmebo S, Johansson I et al.: Cloning and tissue distribution of a novel human cytochrome P450 of the CYP3A subfamily, CYP3A43. Biochem. Biophys. Res. Commun. 281, 1349-1355 (2001).
12. Nebert DW, Russell DW: Clinical importance of the cytochromes P450. Lancet 360, 1155-1162 (2002).
13. Hashimoto H, Toide K, Kitamura R et al.: Gene structure of CYP3A4, an adult-specific form of cytochrome P450 in human livers, and its transcriptional control. Eur. J. Biochem. 218, 585-595 (1993).
14. Bertz RJ, Granneman GR: Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clin. Pharmacokinet. 32, 210-258 (1997).
15. Ortiz de Montellano PR: The 1994 Bernard B. Brodie Award Lecture. Structure, mechanism, and inhibition of cytochrome P450. Drug Metab. Dispos. 23, 1181-1187 (1995).
16. Inaba T, Nebert DW, Burchell B et al.: Pharmacogenetics in clinical pharmacology and toxicology. Can. J. Physiol. Pharmacol. 73, 331-338 (1995).
17. Ozdemir V, Kalowa W, Tang BK et al.: Evaluation of the genetic component of variability in CYP3A4 activity: a repeated drug administration method. Pharmacogenetics 10, 373-388 (2000).
18. Ball SE, Scatina J, Kao J et al.: Population distribution and effects on drug metabolism of a genetic variant in the 5′ promoter region of CYP3A4. Clin. Pharmacol. Ther. 66, 288-294 (1999).
19. Rebbeck TR: More about: modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. J. Natl Cancer Inst. 92, 76 (2000).
20. Sata F, Sapone A, Elizondo G et al.: CYP3A4 allelic variants with amino acid substitutions in exons 7 and 12, evidence for an allelic variant with altered catalytic activity. Clin. Pharmacol. Ther. 67, 48-56 (2000).
21. Rebbeck TR, Jaffe JM, Walker AH, Wein AJ, Malkowicz SB: Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. J. Natl Cancer Inst. 90, 1225-1229 (1998).
22. van Schaik RH, de Wildt SN, Brosens R, van Fessem M, van den Anker JN, Lindemans J: The CYP3A4*3 allele: is it really rare? Clin. Chem. 47, 1104-1106 (2001).
23. Hsieh KP, Lin YY, Cheng CL et al.: Novel mutations of CYP3A4 in Chinese. Drug Metab. Dispos. 29, 268-273 (2001).
24. Eiselt R, Domanski TL, Zibat A et al.: Identification and functional characterization of eight CYP3A4 protein variants. Pharmacogenetics 11, 447-458 (2001).
25. Dai D, Tang J, Rose R et al.: Identification of variants of CYP3A4 and characterization of their abilities to metabolize testosterone and chlorpyrifos. J. Pharmacol. Exp. Ther. 299, 825-831 (2001).
26. Lamba JK, Lin YS, Thummel K et al.: Common allelic variants of cytochrome P4503A4 and their prevalence in different populations. Pharmacogenetics 12, 121-132 (2002).
27. Westlind-Johnsson A, Hermann R, Huennemeyer A et al.: Identification and characterization of CYP3A4*20, a novel rare CYP3A4 allele without functional activity. Clin. Pharmacol. Ther. 79, 339-349 (2006).
28. Zhang JP, Zhou SF, Chen X, Huang M: Determination of intra-ethnic differences in the polymorphisms of thiopurine S-methyltransferase in Chinese. Clin. Chim. Acta 365, 337-341 (2006).
29. Dudbridge F: Pedigree disequilibrium tests for multilocus haplotypes. Genet. Epidemiol. 25, 115-121 (2003).
30. Fukushima-Uesaka H, Saito Y, Watanabe H et al.: Haplotypes of CYP3A4 and their close linkage with CYP3A5 haplotypes in a Japanese population. Hum. Mutat. 23, 100 (2004).
31. Kolars JC, Schmiedlin-Ren P, Schuetz JD, Fang C, Watkins PB: Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes. J. Clin. Invest. 90, 1871-1878 (1992).
32. Boxenbaum H: Cytochrome P450 3A4 in vivo ketoconazole competitive inhibition: determination of Ki and dangers associated with high clearance drugs in general. J. Pharm. Pharm. Sci. 2, 47-52 (1999).
33. Hesse LM, Venkatakrishnan K, von Moltke LL, Shader RI, Greenblatt DJ: CYP3A4 is the major CYP isoform mediating the in vitro hydroxylation and demethylation of flunitrazepam. Drug Metab. Dispos. 29, 133-140 (2001).
34. Plummer SJ, Conti DV, Paris PL, Curran AP, Casey G, Witte JS: CYP3A4 and CYP3A5 genotypes, haplotypes, and risk of prostate cancer. Cancer Epidemiol. Biomarkers Prev. 12, 928-932 (2003).
35. Dhaini HR, Thomas DG, Giordano TJ et al.: Cytochrome P450 CYP3A4/5 expression as a biomarker of outcome in osteosarcoma. J. Clin. Oncol. 21, 2481-2485 (2003).
36. Dally H, Edler L, Jager B et al.: The CYP3A4*1B allele increases risk for small cell lung cancer: effect of gender and smoking dose. Pharmacogenetics 13, 607-618 (2003).
37. Felix CA, Walker AH, Lange BJ et al.: Association of CYP3A4 genotype with treatment-related leukemia. Proc. Natl Acad. Sci. USA 95, 13176-13181 (1998).
38. Walker AH, Jaffe JM, Gunasegaram S et al.: Characterization of an allelic variant in the nifedipine-specific element of CYP3A4: ethnic distribution and implications for prostate cancer risk. Mutations in brief no. 191. Hum. Mutat. 12, 289 (1998).
39. Halushka MK, Fan JB, Bentley K et al.: Patterns of single-nucleotide polymorphisms in candidate genes for blood-pressure homeostasis. Nat. Genet. 22, 239-247 (1999).
40. Phillips KA, Veenstra DL, Oren E, Lee JK, Sadee W: Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review. JAMA 286, 2270-2279 (2001).